Literature DB >> 19841344

Salvage treatment of late neck metastasis in esthesioneuroblastoma: a meta-analysis.

Mitchell R Gore1, Adam M Zanation.   

Abstract

OBJECTIVE: Esthesioneuroblastoma (ENB) is an uncommon tumor of the sinonasal region with a 20% rate of neck metastases. To our knowledge, the rate of neck metastases occurring 6 or more months after diagnosis has not been well characterized. The rate of successful salvage of these late neck metastases, defined in this study as disease-free survival for at least 1 year, has not been previously reported.
DESIGN: Meta-analysis examining 33 articles published since 1990. PATIENTS: A total of 678 patients with ENB with 79 patients with neck metastases occurring 6 or more months after the initial diagnosis.
INTERVENTIONS: Patients were grouped according to treatment with surgery, radiotherapy, or combined surgery and radiotherapy. MAIN OUTCOME MEASURES: The rate of successful salvage of late neck metastases, defined as disease-free survival for at least 1 year, was compared for the 3 treatment groups.
RESULTS: The rate of cervical metastases was 20.2%, with a 12.4% rate of late neck metastases. The combined successful salvage rate for late neck metastases with surgery, radiation, or combined therapy was 31.2%. An odds ratio (OR) analysis revealed that surgery plus radiation provided a statistically significant increase in the rate of successful salvage in patients with late neck metastases, with an OR of 8.6 vs single modality therapy and a number-needed-to-treat of 3. We found no difference in the OR for successful salvage for surgery alone vs radiation alone (OR, 1.5).
CONCLUSION: Treatment of neck metastases occurring 6 or more months after an initial diagnosis of ENB with combined surgery and radiotherapy provides a statistically significant survival advantage vs single-modality therapy.

Entities:  

Mesh:

Year:  2009        PMID: 19841344     DOI: 10.1001/archoto.2009.143

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  6 in total

1.  Risk of Delayed Lymph Node Metastasis in Clinically N0 Esthesioneuroblastoma.

Authors:  Justin G Peacock; William S Harmsen; Michael J Link; Jamie J Van Gompel; Caterina Giannini; Kerry D Olsen; Yolanda I Garces; Michelle A Neben Wittich; Daniel J Ma; Sean S Park; Robert L Foote
Journal:  J Neurol Surg B Skull Base       Date:  2016-07-06

Review 2.  When, how and why to treat the neck in patients with esthesioneuroblastoma: a review.

Authors:  Adam M Zanation; Alfio Ferlito; Alessandra Rinaldo; Mitchell R Gore; Valerie J Lund; Kibwei A McKinney; Carlos Suárez; Robert P Takes; Anand K Devaiah
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-08-13       Impact factor: 2.503

3.  Changing Trends in the Management of Esthesioneuroblastoma: Irish and International Perspectives.

Authors:  Robbie S R Woods; Thavakumar Subramaniam; Mary Leader; Rory McConn-Walsh; James Paul O'Neill; Peter D Lacy
Journal:  J Neurol Surg B Skull Base       Date:  2017-11-01

Review 4.  Esthesioneuroblastoma: Summary of Single-center Experiences with Focus on Adjuvant Therapy and Overall Survival.

Authors:  Hammam A Alotaibi; Stefano M Priola; Anne-Laure Bernat; Faisal Farrash
Journal:  Cureus       Date:  2019-06-13

5.  The Treatment Outcomes of Olfactory Neuroblastoma Patients With Frontal Lobe Invasion.

Authors:  Jie Wang; Li Wang; Huanyu He; Yi Li; Xinmao Song
Journal:  Front Oncol       Date:  2021-07-05       Impact factor: 6.244

Review 6.  Atypical esthesioneuroblastoma invading oral cavity: a case report and review of the literature.

Authors:  Sandra Ventorin von Zeidler; Rafaela Guidi; Rita de Cássia Gonçalves Alencar; Renato Aguiar; Elismauro Francisco Mendonça; Aline Carvalho Batista; Rejane Faria Ribeiro-Rotta
Journal:  Diagn Pathol       Date:  2014-01-20       Impact factor: 2.644

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.